AlzeCure’s ACD856 demonstrates good tolerability in Phase I clinical trial and is approved for additional doses
Stockholm, Sweden, August 27, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received approval from the Medical Products Agency to be able to give additional doses of ACD856 in the clinical phase I study (single ascending dose, SAD) with ACD856, as its good tolerability enables higher doses to be tested.Data from the SAD study establish that ACD856, the lead candidate drug